Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
443.50    -2.50 (-0.56%)
Bid:
437.50
Ask:
443.00
Spread: 5.50 (1.257%)
Market Cap: £218.12m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Operational and Trading Update

5 Nov 2020 07:00

RNS Number : 2892E
Zotefoams PLC
05 November 2020
 

Zotefoams plc

("Zotefoams" or "Group")

 

Operational and Trading Update

 

5 November 2020 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter, ended 30 September 2020.

 

Zotefoams is pleased to report a record third-quarter sales performance, with revenues approximately 22% ahead of Q3 2019. This reflected very strong contributions, as expected, from both personal protective equipment ("PPE") and footwear products. While the large PPE programme runs down through the latter part of 2020, the strong momentum in footwear and T-FIT® insulation products, together with early indications of demand recovery in a number of our markets, supports the Board's continued expectation of strong year-on-year sales growth in Q4. Using current foreign exchange rates and subject to there being no material disruption to the business, the Board expects full-year revenues and underlying profit before tax to be in line with market expectations.

 

Operating cash performance has continued to be solid, with net debt at 30 September 2020 of £36m, in line with management expectations. The strong trading momentum through the second half, together with the effective cash management actions taken, have left the Group in a resilient financial position. The commissioning of our new foam manufacturing site in Poland is in progress, with first product expected to be shipped to customers in early Q1 2021. In addition, the commissioning of the pilot line for our ReZorce® mono-material barrier packaging technology is expected to begin in December with availability for external trials also in Q1 2021.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"2020 has been a difficult year for many businesses. I am pleased Zotefoams' results are demonstrating the wide applicability of our products and the resilience and flexibility of our people. Our current performance allows us to look beyond the current economic circumstances and maintain our strategy of investing in the current year to support the delivery of longer-term growth."

 

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

 

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com 

 

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFLRLRLSIII
Date   Source Headline
13th Jun 20232:55 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
6th Jun 20231:34 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Jun 20238:00 amRNSNike Exclusivity Agreement Extension
24th May 202311:40 amRNSResult of the 2023 Annual General Meeting
24th May 20237:00 amRNSTrading Update and Chair Succession
12th May 202310:42 amRNSNotification Of Transactions Of Directors/PDMRs
27th Apr 20237:00 amRNSHigh-performance foam in medical facility doors
26th Apr 20235:44 pmRNSNotification Of Transactions Of Directors/PDMRs
26th Apr 20233:39 pmRNSNotification Of Transactions Of Directors/PDMRs
24th Apr 20235:50 pmRNSReplacement Notice Transactions Of Directors/PDMRs
24th Apr 20234:42 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Apr 20237:00 amRNS2022 Annual Report and Notice of the 2023 AGM
19th Apr 20234:41 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Apr 20231:18 pmRNSNotification Of Transactions Of Directors/PDMRs
27th Mar 20234:35 pmRNSPrice Monitoring Extension
22nd Mar 20231:30 pmRNSHolding(s) in Company
21st Mar 20234:10 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Mar 20234:09 pmRNSHolding(s) in Company
21st Mar 20237:00 amRNSPreliminary Results
14th Mar 20234:58 pmRNSHolding(s) in Company
14th Mar 20233:09 pmRNSNotification Of Transactions Of Directors/PDMRs
28th Feb 20237:00 amRNSAward of AA ESG Ratings assessment
15th Feb 20237:00 amRNSNotice of Results
14th Feb 20233:34 pmRNSNotification Of Transactions Of Directors/PDMRs
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20237:00 amRNSFull Year Trading Update
17th Jan 20237:00 amRNSChair Succession
12th Jan 202311:18 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20227:00 amRNSTrading Update
13th Dec 20224:03 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Dec 20229:42 amRNSNotification Of Transactions Of Directors/PDMRs
5th Dec 202211:34 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 202211:27 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 20227:00 amRNSAppointment of Joint Broker
9th Nov 20227:00 amRNSAcquisition of the assets and IP of Refour ApS
17th Oct 202211:31 amRNSNotification Of Transactions Of Directors/PDMRs
13th Oct 20227:00 amRNSTrading Update
12th Oct 20224:02 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Oct 20224:41 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSIndependent Life Cycle Assessment of ReZorce
13th Sep 20223:43 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:35 pmRNSPrice Monitoring Extension
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
12th Aug 20221:43 pmRNSDirector/PDMR Shareholding
11th Aug 20223:50 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSInterim Results
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
20th Jul 20224:42 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.